G282-3513 Screening compound: 6-methyl-N1,N6-bis(3-methylbutyl)-8-oxo-7-propyl-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1,6-dicarboxamide

G282-3513 Screening compound: 6-methyl-N1,N6-bis(3-methylbutyl)-8-oxo-7-propyl-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1,6-dicarboxamide
G282-3513 Screening compound: 6-methyl-N1,N6-bis(3-methylbutyl)-8-oxo-7-propyl-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1,6-dicarboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound G282-3513
6-methyl-N1,N6-bis(3-methylbutyl)-8-oxo-7-propyl-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1,6-dicarboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

G282-3513

Molecular Formula

C22H37N5O3 (C22 H37 N5 O3)

Compound Name

6-methyl-N1,N6-bis(3-methylbutyl)-8-oxo-7-propyl-5H,6H,7H,8H-imidazo[1,5-a]pyrazine-1,6-dicarboxamide

IUPAC name

6-methyl-N1N6-bis(3-methylbutyl)-8-oxo-7-propyl-5H6H7H8H-imidazo[15-a]pyrazine-16-dicarboxamide

SMILES

CCCN(C(C)(Cn1c2c(C(NCCC(C)C)=O)nc1)C(NCCC(C)C)=O)C2=O

InChI

InChI=1S/C22H37N5O3/c1-7-12-27-20(29)18-17(19(28)23-10-8-15(2)3)25-14-26(18)13-22(27,6)21(30)24-11-9-16(4)5/h14-16H,7-13H2,1-6H3,(H,23,28)(H,24,30)/t22-/m0/s1

InChI Key

ONOUWXPURHUDFY-QFIPXVFZSA-N

MDL Number (MFCD)

MFCD27213009

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

419.57

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

12.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

2.494

Distribution Coefficient, logD

2.494

Water Solubility, LogSw

-2.51

Polar Surface Area

76.574

Acid Dissociation Constant (pKa)

13.52

Base Dissociation Constant (pKb)

1.48

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

72.70

G282-3513 in Drug Discovery

Included in Screening Libraries

Autophagy-Targeted Library (4564 compounds)

Cyclic Ugi PPI Library (9586 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Protein-Protein Interaction Library (218420 compounds)

Targeted Diversity Library (40567 compounds)

Akt-Targeted Library (14764 compounds)

Developmental Pathway (Hh/Wnt) Set (2238 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Infections
  • Cancer
  • Digestive system
  • Respiratory tract
  • Nervous system
  • Male
  • Female
  • Cardiovascular
  • Skin
  • Metabolic
  • Immune system
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Cancer
  • Digestive system
  • Female
  • Hemic and lymphatic
  • Skin
Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Cyclic compounds
  • Mimetics
  • Mimetics
Targets:
  • Kinases
  • Others

References: we are preparing a list of scientific research reports with G282-3513 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound G282-3513?
Check Price and Availability of G282-3513, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of G282-3513 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for G282-3513
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for G282-3513
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of G282-3513 available by request